Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

OBJECTIVE: In vivo, after subcutaneous injection, insulin glargine (21(A)-Gly-31(B)-Arg-32(B)-Arg-human insulin) is enzymatically processed into 21(A)-Gly-human insulin (metabolite 1 [M1]). 21(A)-Gly-des-30(B)-Thr-human insulin (metabolite 2 [M2]) is also found. In vitro, glargine exhibits slightly...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolli, Geremia B., Hahn, Annke D., Schmidt, Ronald, Eisenblaetter, Tanja, Dahmen, Raphael, Heise, Tim, Becker, Reinhard H.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507590/
https://www.ncbi.nlm.nih.gov/pubmed/23093664
http://dx.doi.org/10.2337/dc12-0270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507590/
https://www.ncbi.nlm.nih.gov/pubmed/23093664
http://dx.doi.org/10.2337/dc12-0270

Ejemplares similares